Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVSEF exchanges : Amex save search
Atopic Dermatitis Drugs Market to grow by USD 4.7 billion from 2022-2027 | North America to account for 36% of market growth- Technavio
Published: 2023-10-17 (Crawled : 05:00) - prnewswire.com
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -0.27%
H: 1.38%
C: 0.83%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.95%
H: 1.81%
C: 0.53%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.2%
H: 0.44%
C: -0.56%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
PHGE | News | $0.2937 4.86% 0.1% 110K
|
Health Technology
|
| O: 5.0%
H: 3.17%
C: -1.56%
america dermatitis market
The Worldwide Diabetic Retinopathy Industry is Expected to Reach $7.7 Billion by 2027 at a 11.3% CAGR
Published: 2022-11-22 (Crawled : 13:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.33%
H: 1.88%
C: 1.53%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.77%
H: 0.41%
C: 0.27%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.66%
H: 0.79%
C: 0.72%
ALIM | $3.4 -4.23% -4.41% 57K
|
Health Technology
|
| O: 0.47%
H: 7.5%
C: -1.17%
expected diabetic
Worldwide Radiotheranostics Industry to 2027 - By Radioisotope, Application, End-user, Competitive Landscape and Region
Published: 2022-11-09 (Crawled : 20:00) - prnewswire.com
TRUMF | $17.112 -17.59% 1.5K
|
Health Technology
|
| O: 2.88%
H: 1.93%
C: -0.99%
TRUMY | $16.69 0.79% 54K
|
Manufacturing
|
| O: 0.27%
H: 3.27%
C: 3.27%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 2.81%
H: 0.43%
C: -0.2%
BSX | $67.42 -0.8% -0.53% 5.9M
|
Health Technology
|
| O: 3.26%
H: 1.01%
C: 0.76%
YMAB | $14.97 -0.93% -0.94% 410K
|
Health Technology
|
| O: 4.96%
H: 9.22%
C: 9.22%
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 5.57%
H: 9.88%
C: 7.49%
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 3.4%
H: 3.63%
C: 2.25%
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab) Bio-Thera Solutions, Ltd. announced that dosing has begun in a Phase I cli...
Published: 2022-10-14 (Crawled : 13:00) - biospace.com/
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.17%
H: 0.8%
C: -0.75%
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: -2.63%
H: 2.37%
C: -2.5%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
DVA | $126.11 -1.2% 0.0% 750K
|
Health Services
|
| O: 0.65%
H: 1.88%
C: -0.77%
VRNA | $16.1 -1.83% -1.86% 490K
|
Health Technology
|
| O: 0.4%
H: 1.39%
C: -0.3%
UTHR | $237.16 0.79% 0.78% 480K
|
Health Technology
|
| O: 0.24%
H: 1.71%
C: 1.01%
NNVC | $1.175 1.29% 0.0% 13K
|
Health Technology
|
| O: 2.34%
H: 0.0%
C: 0.0%
bat2606 nucala solutions biosimilar study
Head and Neck Cancer Market worth $ 9.07 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-03-23 (Crawled : 11:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 3.81%
H: 0.0%
C: -0.44%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -4.55%
H: 6.28%
C: 6.28%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: 0.0%
MGNX | $16.08 -0.12% -0.12% 590K
|
Health Technology
|
| O: -1.31%
H: 3.88%
C: -0.67%
KURA | $17.66 -1.83% -1.87% 1.7M
|
Health Technology
|
| O: -1.34%
H: 0.12%
C: -2.6%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.04%
H: 0.08%
C: -1.26%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.31%
H: 1.85%
C: 1.55%
ADXS | $0.6455 12.48% 2.3K
|
Health Technology
|
| O: -1.64%
H: 8.33%
C: 0.0%
CVM | $1.5 1.33% 160K
|
Health Technology
|
| O: -0.92%
H: 2.31%
C: -3.47%
report cancer market
AavantiBio Announces Formation of Scientific Advisory Board
Published: 2022-02-09 (Crawled : 14:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: 0.0%
IBIO | $1.77 -6.35% -0.57% 180K
|
Health Technology
|
| O: 2.98%
H: 0.0%
C: 0.0%
ces
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.